<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002020'>Gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>) is defined as a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications </plain></SENT>
<SENT sid="1" pm="."><plain>In the last decade, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> has been increasing in Korea </plain></SENT>
<SENT sid="2" pm="."><plain>Seventeen consensus statements for the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> were developed using the modified Delphi approach </plain></SENT>
<SENT sid="3" pm="."><plain>Acid suppression treatments, such as <z:chebi fb="0" ids="49200">proton pump inhibitors</z:chebi> (<z:chebi fb="4" ids="53266">PPIs</z:chebi>), histmine-2 receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> and antacids are effective in the control of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>-related symptoms </plain></SENT>
<SENT sid="4" pm="."><plain>Among them, <z:chebi fb="4" ids="53266">PPIs</z:chebi> are the most effective medication </plain></SENT>
<SENT sid="5" pm="."><plain>Standard dose <z:chebi fb="4" ids="53266">PPI</z:chebi> is recommended as the initial treatment of erosive <z:hpo ids='HP_0100633'>esophagitis</z:hpo> (for 8 weeks) and non-erosive reflux disease (at least for 4 weeks) </plain></SENT>
<SENT sid="6" pm="."><plain>Long-term continuous <z:chebi fb="4" ids="53266">PPI</z:chebi> or on-demand therapy is required for the majority of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> patients after the initial treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Anti-reflux surgery can be considered in well selected patients </plain></SENT>
<SENT sid="8" pm="."><plain>Prokinetic agents and mucosal protective drugs have limited roles </plain></SENT>
<SENT sid="9" pm="."><plain>Twice daily <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy can be tried to control extra-esophageal symptoms of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>For symptomatic patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, long-term treatment with <z:chebi fb="4" ids="53266">PPI</z:chebi> is required </plain></SENT>
<SENT sid="11" pm="."><plain>Further studies are strongly needed to develop better treatment strategies for Korean patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> </plain></SENT>
</text></document>